Table 2.
Clinical characteristics stratified by lower limb lymphedema (LLL) status
| Variable | Total Sample (n=213) |
LLL (n=77) |
No LLL (n=136) |
Pa |
|---|---|---|---|---|
| Pathology type — no. (%) | .73 | |||
| Endometroid Adenocarcinoma | 158 (75%) | 57 (74%) | 101 (75%) | |
| Papillary serous or Clear Cell | 35 (17%) | 14 (18%) | 21 (16%) | |
| Sarcoma | 8 (4%) | 2 (3%) | 6 (4%) | |
| Carcinosarcoma | 8 (4%) | 2 (3%) | 6 (4%) | |
| Other (Undifferentiated) | 3 (1%) | 2 (3%) | 1 (1%) | |
| Stage — no. (%) | .76 | |||
| 1 | 157 (74%) | 57 (74%) | 100 (74%) | |
| 2 | 13 (6%) | 5 (6%) | 8 (6%) | |
| 3 | 26 (12%) | 9 (12%) | 17 (13%) | |
| 4 | 5 (2%) | 3 (4%) | 2 (1%) | |
| Unknown | 12 (6%) | 3 (4%) | 9 (7%) | |
| Treatment Modalities — no. (%) | .51 | |||
| Surgery | 100 (47%) | 40 (52%) | 60 (44%) | |
| Surgery, Chemotherapy | 37 (17%) | 12 (16%) | 25 (18%) | |
| Surgery, Radiation | 47 (22%) | 13 (17%) | 34 (25%) | |
| Surgery, Chemotherapy, Radiation | 22 (10%) | 10 (13%) | 12 (9%) | |
| None or Unknown | 7 (3%) | 2 (3%) | 5 (4%) | |
| No. of nodes removed | 8.9±10.2 | 7.6±9.8 | 9.7±10.4 | .10 |
| Neuropathy Impairment Indexb | 3.3±3.6 | 2.8±3.4 | 3.6±3.7 | .17 |
| Time since diagnosis — no. (%) | .74 | |||
| 0–2 yrs | 69 (32%) | 23 (30%) | 46 (34%) | |
| 3–4 yrs | 94 (44%) | 34 (44%) | 60 (44%) | |
| 5–6 yrs | 50 (23%) | 20 (26%) | 30 (22%) | |
| BMI — kg/m2 | 31.1±8.9 | 30.8±9.3 | 31.2±8.7 | .66 |
| Prior comorbiditiesc — no. (%) | ||||
| Congestive heart failure | 8 (4%) | 2 (3%) | 6 (5%) | .50 |
| Peripheral artery disease | 5 (2%) | 3 (4%) | 2 (2%) | .27 |
| Diabetes mellitus | 29 (14%) | 11 (15%) | 18 (14%) | .82 |
a
By Wilcoxon rank sum, or Fishers Exact test. Values may not sum to 213 or 100% due to rounding error and item non-response.
b
The neuropathy impairment index is scored from 0 to 16 with higher scores representing more severe neuropathy in the hands and feet.
c
Comorbidities associated with symptoms in the lower limbs that may resemble lower limb lymphedema.